Response to a Letter to the Editor Entitled “Low Serum B12 Level Does Not Mean Vit. B12 Deficiency-Problems Related to the Diagnosis of Vitamin B12 Deficiency”

Öner, Veysi; Türkyılmaz, Kemal; Turkyilmaz, Aysegul Kucukali; Kırbaş, Aynur; Kırbaş, Serkan; Şekeryapan, Berrak

doi:10.3109/02713683.2013.833249

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TCN1 is a vitamin B12-binding protein that is present in the cytoplasm and performs functions with TCN2 and intrinsic factors in the processes of cobalamin transport, metabolism, and homeostasis 13,14 . Studies have shown aberrant serum levels of vitamin B12 and TCN1 in some solid tumours [15][16][17][18][19] .…”

Section: Discussionmentioning

confidence: 99%

High expression of TCN1 is a negative prognostic biomarker and can predict neoadjuvant chemosensitivity of colon cancer

Liu

Wang

Yue

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Transcobalamin (TCN1) is a vitamin B12 (cobalamin)-binding protein that regulates cobalamin homeostasis. Recent studies and bioinformatic analyses have found that TCN1 is highly expressed in cancer tissues and is associated with tumour aggressiveness and poor prognosis. the present study aimed to detect TCN1 as a novel biomarker for prognosis and chemosensitivity of colon cancer. nextgeneration sequencing showed that TCN1 was one of several upregulated mRnAs in colon cancer, which was verified by further bioinformatics analyses. Western blotting (n = 9) and quantitative real time polymerase chain reaction (qRT-PCR, n = 30) revealed that TCN1 was highly expressed in colon cancer tissues at both the protein and mRNA level. A total of 194 cases of colon cancer were examined by immunohistochemistry and revealed that TCN1 expression level was related to advanced stages (P < 0.005). Kaplan-Meier analysis verified that patients with lower TCN1 expression usually had longer overall survival (P = 0.008). In addition, TCN1 was highly expressed in pulmonary metastatic tumour tissues (n = 37, P = 0.025) and exhibited higher levels in right-sided colon cancer than in left-sided colon cancer (P = 0.029). TCN1 expression in specimens that had received neoadjuvant chemotherapy decreased compared with that in colonoscopy biopsy tissues (n = 42, P = 0.009). Further bioinformatics analyses verified that apoptosis pathways might have a role in high TCN1 expression. All the studies revealed that TCN1 expression in colon cancer was significantly associated with malignant biological behaviour. Therefore, TCN1 could be used as a novel biomarker for colon cancer aggressiveness and prognosis and might also be a potential biomarker for predicting neoadjuvant chemosensitivity. According to the data from GLOBOCAN 2018, colorectal cancer (CRC) is one of the most common intestinal tumours and ranks as the fourth leading cause of morbidity and the second leading cause of cancer-related mortality worldwide 1. Despite major developments in surgery and therapeutics, long-term survival remains far from satisfactory 2,3 , mainly because CRC is often detected at more advanced stages. Currently, diagnosis, relapse, and metastasis monitoring of CRC largely relies on colonoscopy and imaging data, which is usually delayed. Therefore, new sensitive biomarkers are urgently required to ensure early diagnosis and to predict progression and administer timely treatments. Transcobalamin I (TCN1) is a type of vitamin B12 (cobalamin)-binding protein that transports cobalamin from the stomach to the intestines. It plays various roles in maintaining the basic function of cell proliferation and

show abstract